JP7499755B2 - 金（ｉｉｉ） 錯体、金（ｉｉｉ） 錯体のコンジュゲート、金（ｉｉｉ） 錯体を含む医薬組成物、金（ｉｉｉ） 錯体を生成する方法とその使用。 - Google Patents

金（ｉｉｉ） 錯体、金（ｉｉｉ） 錯体のコンジュゲート、金（ｉｉｉ） 錯体を含む医薬組成物、金（ｉｉｉ） 錯体を生成する方法とその使用。 Download PDF

Info

Publication number
JP7499755B2
JP7499755B2 JP2021510529A JP2021510529A JP7499755B2 JP 7499755 B2 JP7499755 B2 JP 7499755B2 JP 2021510529 A JP2021510529 A JP 2021510529A JP 2021510529 A JP2021510529 A JP 2021510529A JP 7499755 B2 JP7499755 B2 JP 7499755B2
Authority
JP
Japan
Prior art keywords
iii
gold
independently selected
complexes
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021510529A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523936A (ja
JP2021523936A5 (https=
JPWO2019211222A5 (https=
Inventor
ゴンザレズ，サラ マリア ソト
ロンカン，カルロス ラティア
ロペス，ビリジニオ セパス
クビロス，ユリ ロペス
オルティス，フェルナンド ロペス
バルデシロス，マリア ホセ イグレシアス
ソエンガス，ラクエル マリア ゴンザレス
Original Assignee
ユニベルシダト デ アルメリア
ファンダシオン プリヴァーダ インスチツート デ サルード グローバル バルセロナ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニベルシダト デ アルメリア, ファンダシオン プリヴァーダ インスチツート デ サルード グローバル バルセロナ filed Critical ユニベルシダト デ アルメリア
Publication of JP2021523936A publication Critical patent/JP2021523936A/ja
Publication of JP2021523936A5 publication Critical patent/JP2021523936A5/ja
Publication of JPWO2019211222A5 publication Critical patent/JPWO2019211222A5/ja
Application granted granted Critical
Publication of JP7499755B2 publication Critical patent/JP7499755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/12—Gold compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N57/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
    • A01N57/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having alternatively specified atoms bound to the phosphorus atom and not covered by a single one of groups A01N57/10, A01N57/18, A01N57/26, A01N57/34
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N57/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
    • A01N57/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having alternatively specified atoms bound to the phosphorus atom and not covered by a single one of groups A01N57/10, A01N57/18, A01N57/26, A01N57/34
    • A01N57/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having alternatively specified atoms bound to the phosphorus atom and not covered by a single one of groups A01N57/10, A01N57/18, A01N57/26, A01N57/34 containing heterocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/67—Phosphorus compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5463—Compounds of the type "quasi-phosphonium", e.g. (C)a-P-(Y)b wherein a+b=4, b>=1 and Y=heteroatom, generally N or O
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
JP2021510529A 2018-05-03 2019-04-29 金（ｉｉｉ） 錯体、金（ｉｉｉ） 錯体のコンジュゲート、金（ｉｉｉ） 錯体を含む医薬組成物、金（ｉｉｉ） 錯体を生成する方法とその使用。 Active JP7499755B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382305.3A EP3564246B1 (en) 2018-05-03 2018-05-03 A gold(iii) complex, a conjugate of the gold(iii) complex, a pharmaceutical composition comprising the gold(iii) complex and uses and a process for preparing the gold(iii) complex
EP18382305.3 2018-05-03
PCT/EP2019/060879 WO2019211222A1 (en) 2018-05-03 2019-04-29 A gold(iii) complex, a conjugate of the gold(iii) complex, a pharmaceutical composition comprising the gold(iii) complex and uses and a process for preparing the gold(iii) complex

Publications (4)

Publication Number Publication Date
JP2021523936A JP2021523936A (ja) 2021-09-09
JP2021523936A5 JP2021523936A5 (https=) 2022-04-05
JPWO2019211222A5 JPWO2019211222A5 (https=) 2022-04-05
JP7499755B2 true JP7499755B2 (ja) 2024-06-14

Family

ID=62222548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510529A Active JP7499755B2 (ja) 2018-05-03 2019-04-29 金（ｉｉｉ） 錯体、金（ｉｉｉ） 錯体のコンジュゲート、金（ｉｉｉ） 錯体を含む医薬組成物、金（ｉｉｉ） 錯体を生成する方法とその使用。

Country Status (10)

Country Link
US (1) US11866455B2 (https=)
EP (1) EP3564246B1 (https=)
JP (1) JP7499755B2 (https=)
KR (1) KR20210008020A (https=)
CN (1) CN112638922B (https=)
CA (1) CA3098778A1 (https=)
DK (1) DK3564246T3 (https=)
ES (1) ES2893849T3 (https=)
MX (1) MX2020011557A (https=)
WO (1) WO2019211222A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022072545A1 (en) * 2020-09-29 2022-04-07 University Of Kentucky Research Foundation Multi-coordinate gold-phosphine compounds and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9709471A (es) * 1995-06-07 1998-02-28 Univ Washington Complejos metalicos multidentados y metodos para preparar y usar los mismos.
GB0900961D0 (en) * 2009-01-20 2009-03-04 Univ Bath Antimicrobial coating
WO2013091014A1 (en) * 2011-12-22 2013-06-27 James Cook University Antimicrobial agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRIK, M. et al.，CyclometalatedIminophosphorane Gold(III) and Platinum(II) Complexes. A Highly PermeableCationic Platinum(II) Compound with Promising Anticancer Properties，Journal ofMedicinal Chemistry ，2015年，Vol.58, No.15，pp.5825-5841 ，DOI: 10.1021/acs.jmedchem.5b00427
PARISH, R. et al.，Chemicaland Biological Studies of Dichloro(2-((dimethylamino)methyl)phenyl)gold(III)，InorganicChemistry，1996年，Vol.35, No.6，pp.1659-1666 ，DOI:10.1021/ic950343b
SHAIK, N. et al.，Synthesisof Apoptosis-Inducing Iminophosphorane Organogold(III) Complexes and Study ofTheir Interactions with Biomolecular Targets ，Inorganic Chemistry，2009年，Vol.48, No.4，pp.1577-1587，DOI: 10.1021/ic801925k

Also Published As

Publication number Publication date
EP3564246B1 (en) 2021-07-07
JP2021523936A (ja) 2021-09-09
ES2893849T3 (es) 2022-02-10
CA3098778A1 (en) 2019-11-07
KR20210008020A (ko) 2021-01-20
CN112638922B (zh) 2024-04-05
US11866455B2 (en) 2024-01-09
BR112020022402A2 (pt) 2021-02-02
DK3564246T3 (da) 2021-08-09
MX2020011557A (es) 2021-01-29
US20210188886A1 (en) 2021-06-24
EP3564246A1 (en) 2019-11-06
CN112638922A (zh) 2021-04-09
WO2019211222A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
Lam et al. Development of ruthenium (II) complexes as topical antibiotics against methicillin resistant Staphylococcus aureus
Chavain et al. Organometallic complexes: new tools for chemotherapy
Gholivand et al. Two novel Ag (I) complexes of N-nicotinyl phosphoric triamide derivatives: Synthesis, X-ray crystal structure and in vitro antibacterial and cytotoxicity studies
Nareetsile et al. Metallo-drugs as promising antibacterial agents and their modes of action
Rusu et al. Development perspectives of silver complexes with antibacterial quinolones: Successful or not?
Stevanović et al. Clinically used antifungal azoles as ligands for gold (iii) complexes: The influence of the Au (iii) ion on the antimicrobial activity of the complex
Karpin et al. Transition metal diamine complexes with antimicrobial activity against Staphylococcus aureus and methicillin-resistant S. aureus (MRSA)
Medici et al. Noble metals in pharmaceuticals: Applications and limitations
Mensah et al. A Ru (ii)-arene-ferrocene complex with promising antibacterial activity
Zhao et al. Anti-tumoral titanium (IV) complexes stabilized with phenolato ligands and structure-activity relationship
JP2004510778A (ja) 抗腫瘍剤としての白金錯体
KR20140123081A (ko) 아미노산과 카르복실산을 포함한 게르마늄의 착체 및 이를 제조하는 방법
JP7499755B2 (ja) 金（ｉｉｉ） 錯体、金（ｉｉｉ） 錯体のコンジュゲート、金（ｉｉｉ） 錯体を含む医薬組成物、金（ｉｉｉ） 錯体を生成する方法とその使用。
Neshat et al. Homobimetallic Au (I)–Au (I) and heterotrimetallic Au (I)–Fe (II)–Au (I) complexes with dialkyldithiophosphates and phosphine ligands: structural characterization, DFT analysis, and tyrosinase inhibitory and biological effects
Das et al. Deciphering the Mechanism of MRSA Targeting Copper (II) Complexes of NN 2 Pincer-Type Ligands
EP0481994A1 (en) Metallo-organic cobalt compounds and uses thereof
US11779598B2 (en) Synthesis and antimicrobial uses of dinuclear silver(I) pyrazolates
Sekhon Metalloantibiotics and antibiotic mimics-an overview
Takayama et al. Synthesis, structure and antimicrobial activity of L-argininesilver (1+) nitrate
Sabounchei et al. N-Containing Ag (I) and Hg (II) Complexes: A New Class of Antibiotics
Kumar et al. Role of metallodrugs in medicinal inorganic chemistry
BR112020022402B1 (pt) Complexo de ouro(iii), conjugado, composição farmacêutica, uso do complexo de ouro(iii) e processo para a preparação do complexo de ouro(iii)
Stryjska et al. Checi nska, L.; Kusz, J.; Ochocki, J. Synthesis, Spectroscopy, Single-Crystal Structure Analysis and Antibacterial Activity of Two Novel Complexes of Silver (I) with Miconazole Drug
CA2972079A1 (en) A potent synthetic inorganic antibacterial with activity against drug-resistant pathogens
US8048870B2 (en) Apoptosis-inducing antineoplastic silver (I) coordination complexes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240103

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240604